文献速递白血病MDS 与骨髓增殖性肿瘤

克隆性造血作为接受化疗(免疫)治疗的慢性淋巴细胞白血病患者治疗相关髓系肿瘤的风险因素

Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
PubMed 文献 · Br J Haematol · 2022-03-11

研究采用靶向二代测序和微滴式数字PCR,分析接受化疗(免疫)治疗后发生治疗相关髓系肿瘤(t-MN)的慢性淋巴细胞白血病(CLL)患者的髓系基因突变谱。13例t-MN患者中10例(77%)检出30个致病/可能致病变异,中位变异数2个(范围0-6)。8例有CLL诊断时配对样本的患者中,6例在t-MN时携带至少一个CHIP变异,5例CLL样本中检出相同变异。基于人群的CLL队列285例中34例携带CHIP变异,t-MN患者CHIP患病率显著高于人群队列(5/8,62.5% vs 34/285,12%,p=0.0001)。

要点

  • 13例t-MN患者中10例(77%)检出致病/可能致病变异,中位2个(范围0-6)。
  • 8例配对样本中6例在t-MN时携带CHIP变异,5例CLL样本中检出相同变异。
  • t-MN患者CHIP患病率5/8(62.5%)显著高于人群CLL队列34/285(12%),p=0.0001。

核心结论

  • CHIP或可作为影响CLL患者治疗决策的新参数,并提示在CHIP阳性病例中采用无化疗方案的潜力。

研究设计与样本

  • 采用靶向二代测序(t-NGS)panel和微滴式数字PCR(ddPCR)研究接受化疗(免疫)治疗后发生t-MN的CLL患者的髓系基因突变谱。
  • 13例t-MN患者中10例(77%)检出30个致病/可能致病变异,中位变异数2个(范围0-6)。
  • 8例有CLL诊断时配对样本的患者中,6例在t-MN时携带至少一个CHIP变异(中位2个,范围1-5),5例CLL样本中检出相同变异。
  • 基于人群的CLL队列285例中34例携带CHIP变异。

主要发现

  • 13例t-MN患者中10例(77%)检出30个致病/可能致病变异,中位变异数2个(范围0-6)。
  • 8例配对样本中6例在t-MN时携带至少一个CHIP变异(中位2个,范围1-5),5例CLL样本中检出相同变异。
  • t-MN患者CHIP患病率5/8(62.5%)显著高于人群CLL队列34/285(12%),p=0.0001。

临床怎么用

  • 作者认为CHIP或可作为影响CLL患者治疗决策的新参数,并提示在CHIP阳性病例中采用无化疗方案的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia (CLL) who developed a t-MN after treatment with chemo-(immuno)therapy. Using NGS, we detected a total of 30 pathogenic/likely pathogenic (P/LP) variants in 10 of 13 patients with a t-MN (77%, median number of variants for patient: 2, range 0-6). The prevalence of CHIP was then backtracked in paired samples taken at CLL diagnosis in eight of these patients. Six of them carried at least one CHIP-variant at the time of t-MN (median: 2, range: 1-5), and the same variants were present in the CLL sample in five cases. CHIP variants were present in 34 of 285 patients from a population-based CLL cohort, which translates into a significantly higher prevalence of CHIP in patients with a CLL who developed a t-MN, compared to the population-based cohort (5/8, 62.5% vs. 34/285, 12%, p = 0.0001). Our data show that CHIP may be considered as a novel parameter affecting treatment algorithms in patients with CLL, and highlight the potential of using chemo-free therapies in CHIP-positive cases.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Voso MT, Pandzic T, Falconi G, et al. Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. Br J Haematol. 2022. PMID: 35277855. doi:10.1111/bjh.18129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。